Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Benoit Colinet"'
Publikováno v:
Breathe, Vol 16, Iss 2 (2020)
Externí odkaz:
https://doaj.org/article/077ba85fabd64e7085c224c3d901b3cf
Autor:
Jacques De Grève, Jan Van Meerbeeck, Johan F Vansteenkiste, Lore Decoster, Anne-Pascale Meert, Peter Vuylsteke, Christian Focan, Jean-Luc Canon, Yves Humblet, Guy Berchem, Benoit Colinet, Danny Galdermans, Lionel Bosquée, Joanna Vermeij, Alex Dewaele, Caroline Geers, Denis Schallier, Erik Teugels
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0147599 (2016)
INTRODUCTION:Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR activating tyrosine kinase domain mutations. Most data available pertain to
Externí odkaz:
https://doaj.org/article/d77d90c2874a41ca9219fe0d09d1012a
Autor:
Thierry Berghmans, Jean-Jacques Lafitte, Arnaud Scherpereel, Lieveke Ameye, Marianne Paesmans, Anne-Pascale Meert, Benoit Colinet, Christian Tulippe, Luc Willems, Nathalie Leclercq, Jean-Paul Sculier, for the European Lung Cancer Working Party
Publikováno v:
ERJ Open Research, Vol 1, Iss 2 (2015)
Salvage chemotherapy (CT) for relapsing or refractory small cell lung cancer (SCLC) remains disappointing. In vitro experiments showed that valproic acid increases apoptosis of SCLC cell lines exposed to doxorubicin, vindesine and bis(2-chloroethyl)a
Externí odkaz:
https://doaj.org/article/bb22aba710104b5682bec48263f17450
Autor:
Peter Driesen, Marc Lambrechts, Kees Kraaij, Victoria Soldatenkova, Nadia Chouaki, Benoit Colinet
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 5 (2013)
Objectives: The aim of this study was to evaluate the efficacy and tolerability of the combination of cisplatin–gemcitabine with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC). Methods: This was a phase
Externí odkaz:
https://doaj.org/article/f479eedee3da4742a6f53a27506bae08
Publikováno v:
Acta clinica Belgica
Objectives: The aim of ASTRIS, a real-world study, was to assess the safety and efficacy of osimertinib in patients with locally advanced or metastatic (stage IIIB-IV) epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lun
Autor:
Anne Sibille, Frederique Bustin, Luciano Carestia, Gaetan Catala, Christophe Compère, Kristof Cuppens, Benoit Colinet, Stephanie Coulon, Nele De Brucker, Lore Decoster, Lynn Decoster, Ingel Demedts, Sofie Derijcke, Koen Deschepper, Danny Galdermans, Annelies Janssens, Sebahat Ocak, Christel Oyen, Karin Pat, Thierry Pieters, Vincent Pruniau, Veerle Surmont, Saar Vandekeere, Johan Vansteenkiste
Publikováno v:
Acta oncologica
Acta oncologica (Stockholm, Sweden), Vol. 61, no. 6, p. 773-776 (2022)
Acta oncologica (Stockholm, Sweden), Vol. 61, no. 6, p. 773-776 (2022)
Medical writing and editorial assistance were provided by Tim Ibbotson, PhD, of ApotheCom (Yardley, PA, USA) and funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Statistical analysis was done by Herbert Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaa79d19a81a12ecdb48210dc208165b
Autor:
Gabriela Beniuga, Nicolas Tinton, Sabrina Urso, Thomas Valembois, Lancelot Marique, Benoit Colinet, Arnaud Ghilain, Inès Dufour
Publikováno v:
Case Reports in Surgery, Vol 2021 (2021)
Case reports in surgery, Vol. 2021, no.2021, p. 6698361 (2021)
Case Reports in Surgery
Case reports in surgery, Vol. 2021, no.2021, p. 6698361 (2021)
Case Reports in Surgery
Background. Herniation of the liver through the anterior abdominal wall is an extremely rare phenomenon. Most cases occur within an incisional hernia (mostly upper abdomen surgery or cardiac surgery). Only two reports mentioned liver herniation witho
Autor:
Caroline Nickner, Åslaug Helland, Konstantin Laktionov, Christina Appenzeller, Maya Gottfried, Zanete Zvirbule, Zhaowen Sun, Cor van der Leest, David Maag, Patricia Rich, Alena Vajikova, Benoit Colinet, Hervé Lena, Philip Komarnitsky, Jen Yu Hung, Vanesa Gutiérrez, Yan Luo, Byoung Chul Cho, Melissa Lynne Johnson, Isamu Okamoto, Martin Wolf, Jair Bar
Introduction Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting DLL3, an atypical Notch ligand expressed in SCLC tumors. We evaluated the efficacy of Rova-T versus placebo as maintenance therapy in patients with extensive-stage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86ac72b3b5a5194730ae4d89381fe419
http://hdl.handle.net/10852/91515
http://hdl.handle.net/10852/91515
Publikováno v:
Breathe
article-version (VoR) Version of Record
Breathe, Vol 16, Iss 2 (2020)
article-version (VoR) Version of Record
Breathe, Vol 16, Iss 2 (2020)
A 71-year-old man came to our pulmonary consultation with 6 weeks of progressive dyspnoea, hoarseness and, more recently, stridor. His past medical history included colorectal cancer treated with surgery and adjuvant chemotherapy, and type 2 diabetes
Autor:
Martin Sebastian, Sofie Derijcke, Laurent Greillier, J. Jürgens, Jaafar Bennouna, C. Debruyne, Niels Reinmuth, Benoit Colinet, Maurice Pérol, Xavier Quantin, D. Moro-Sibilot, A. Sibille, M. Genin, Johan Vansteenkiste, Hervé Lena, J. Plumas, Ingel K. Demedts
Publikováno v:
Journal of Thoracic Oncology. 16:S798-S799